Zobrazeno 1 - 10
of 47
pro vyhledávání: '"David F. Claxton"'
Autor:
Pinyi Lu, Longgui Chen, Barbara A. Miller, Zhongming Zhao, Charyguly Annageldiyev, Melat T. Gebru, Christopher M. Dower, Jennifer M. Atkinson, Arati Sharma, Megan M. Young, Zhenyuan Tang, Hong Gang Wang, Lijun Zhang, David F. Claxton, Yuka Imamura Kawasawa, Zhenqiu Liu
Publikováno v:
Blood
FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a15350f4c228b28961190773dd4afe
https://europepmc.org/articles/PMC7453151/
https://europepmc.org/articles/PMC7453151/
Autor:
Primo N. Lara, Mark Kirschbaum, Timothy W. Synold, David R. Gandara, David F. Claxton, Joseph Tuscano, Jasmine Zain, Paul Frankel, Edward M. Newman
Publikováno v:
British Journal of Haematology. 180:445-448
Autor:
Shin Mineishi, Gina Mackey, W. Christopher Ehmann, Christopher J Pizzola, Witold B. Rybka, Brook Silar, Kevin Rakszawski, Kentaro Minagawa, Hong Zheng, Baldeep Wirk, Seema Naik, David F. Claxton
Publikováno v:
Blood. 134:5724-5724
Introduction: Non-myeloablative conditioning regimens enable elderly and younger patients with significant comorbidities to undergo allogenic stem cell transplant (allo SCT). These regimens allow for the benefit of graft-versus-leukemia (GVL) effect
Autor:
Rami S. Komrokji, Selina M. Luger, Jessica K. Altman, John M. Bennett, Martin S. Tallman, Jaroslaw P. Maciejewski, Kathy L. McGraw, Mark R. Litzow, David F. Claxton, Puneet Cheema, Charles A. Schiffer, Ryan J. Mattison, Andrew S. Artz, Amit Verma, Zhuoxin Sun, Alan F. List, Timothy R. Wassenaar
Publikováno v:
Blood. 134:842-842
Background: Only a small subset of Lower risk (LR) MDS patients benefit from treatment with rhu-Erythropoietin (Epo). We previously reported that lenalidomide (LEN) restores sensitivity to Epo in MDS progenitors by inducing the formation of lipid raf
Autor:
Selina M. Luger, Jessica K. Altman, John E. Godwin, Kristen M. O'Dwyer, Yishai Ofran, James M. Foran, Martin S. Tallman, Hillard M. Lazarus, Janis Racevskis, David F. Claxton, Daniel A. Arber, Elisabeth Paietta, Mark R. Litzow, Keith W. Pratz, Zhuoxin Sun, Aref Al-Kali, Hong Zheng, Bayard L. Powell, Jacob M. Rowe, Edward R. Broun
Publikováno v:
Blood. 134:115-115
Background: Relapse remains the most common cause of treatment failure after intensive induction and consolidation (CONS) therapy in older adults with AML. We therefore performed a prospective randomized phase II study to determine the safety and imp
Autor:
Junjia Zhu, Natthapol Songdej, Hong Zheng, Raymond J. Hohl, Chenchen Zhao, David F. Claxton, Seema Naik, W. Christopher Ehmann, Bei Jia, Shin Mineishi
Publikováno v:
Blood. 134:3939-3939
Introduction: Treatment of AML remains challenging. Decitabine is a hypomethylating agent (HMA) commonly used for treating AML. However, its efficacy is limited. Recent success targeting immune checkpoints offers great promise and several agents bloc
Autor:
Anna C. Salzberg, Elliot M. Epner, Matthew Nemesure, David F. Claxton, W. Christopher Ehmann, Joseph J. Drabick, Jeffrey J Pu, Yuka I Kawasawa
Publikováno v:
Blood. 132:5295-5295
Introduction: Mantle cell lymphoma (MCL) is a malignancy of monomorphic small to medium-sized B lymphocytes and is considered incurable with standard chemotherapy. Median survival estimates are three to seven years, with even shorter survival times i
Autor:
Witold B. Rybka, Chenchen Zhao, Raymond J. Hohl, Shin Mineishi, Hong Zheng, Liru Wang, David F. Claxton, Natthapol Songdej, Seema Naik, W. Christopher Ehmann, Muhammad Rizwanulhaq Khawaja, Bei Jia
Publikováno v:
Blood. 132:1526-1526
Treatment for elderly AML patients who are unfit for intensive chemotherapy remains challenging. Induction with hypomethylating agents (HMA) are the most commonly used approach, however the rate of complete remission (CR) is only around 20% and media
Autor:
Elisabeth Paietta, Yanming Zhang, Selina M. Luger, Martin S. Tallman, James M. Foran, Hillard M. Lazarus, Janis Racevskis, Daniel A. Arber, Mark R. Litzow, Keith W. Pratz, David F. Claxton, John E. Godwin, Jacob M. Rowe, Zhuoxin Sun
Publikováno v:
Blood. 132:3995-3995
Background Activating mutations in FLT3 - and in particular FLT3-ITD (internal tandem duplication) - are common in younger patients with AML, and are associated with relapse and with inferior overall survival (OS), however their prevalence and impact
Autor:
Maria R. Baer, Lori J. Maness, Judy H. Chiao, Donald P. Quick, Farhad Ravandi, Marc Buyse, Stephen A. Strickland, Selina M. Luger, Aleksandra Butrym, David F. Claxton, Pau Montesinos, Gary J. Schiller, Gianluca Gaidano, Karen Seiter, Daniel-Eric Robert, Jessica K. Altman, Hagop M. Kantarjian, Ellin Berman, Stephen E. Rubenstein, Martha Arellano, David A. Rizzieri, Marc Gautier, Xavier Thomas, Kebede H. Begna, Parameswaran Venugopal, Mikkael A. Sekeres, Tapan M. Kadia, Edward Agura, Stuart L. Goldberg, Yosr Hicheri, Janakiraman Subramanian, Scott R. Solomon
Publikováno v:
Blood. 130:891-891
Background: Sapacitabine is a novel oral nucleoside analogue with a unique ability to induce single-strand DNA breaks after incorporation into DNA, leading to production of double-strand DNA breaks and/or G2 cell cycle arrest. In AML cell lines, the